Close Menu

NEW YORK (GenomeWeb) – Talis Biomedical said today that CARB-X has awarded it $4.4 million to further its point-of-care technology for pathogen identification and antibiotic-susceptibility testing.

The award will go toward development of Talis Bio's rapid CLIA-waived molecular diagnostic test for detecting chlamydia and gonorrhea directly from a patient's sample in no more than 20 minutes, as well as a rapid phenotypic antibiotic susceptibility test for gonorrhea.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.